Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-11-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancercell lungsmall cellnon smallnsclc
  Phrases that lowered it: blood pressurefemalemmdays beforehepatic
• Sponsor's past termination rate: 30.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.4% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 11164 (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 22 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 84.3% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 30466 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer NCT00738387 · started 2008 · scored riskier than 93% of active trials terminated
• Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC NCT02504489 · started 2015 · scored riskier than 77% of active trials completed
• Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment NCT00840125 · started 2009 · scored riskier than 95% of active trials completed
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer NCT00662597 · started 2008 · scored riskier than 77% of active trials terminated
• A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC NCT02346370 · started 2015 · scored riskier than 61% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.